Semaglutide for Weight Reduction in Type 1 Diabetes: Promising Results With Uncertain Glycemic Impact.
作者信息
Orrange Sharon, Humphrey Tess, Fayne Ethan, Peters Anne
机构信息
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, USA.
出版信息
J Diabetes Sci Technol. 2025 Mar;19(2):593-594. doi: 10.1177/19322968241304779. Epub 2024 Dec 10.
Abstract
摘要
相似文献
1
Semaglutide for Weight Reduction in Type 1 Diabetes: Promising Results With Uncertain Glycemic Impact.司美格鲁肽用于1型糖尿病减重：效果 promising，但对血糖的影响尚不确定
J Diabetes Sci Technol. 2025 Mar;19(2):593-594. doi: 10.1177/19322968241304779. Epub 2024 Dec 10.
2
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
3
Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.与度拉糖肽、司美格鲁肽和利拉鲁肽相关的精神和心理不良反应：一项药物不良反应全球数据库研究
Clin Nutr. 2025 Aug;51:252-265. doi: 10.1016/j.clnu.2025.06.011. Epub 2025 Jun 23.
4
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
5
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病血糖控制、体重和血脂水平的比较疗效：系统评价和网状Meta分析
BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.
6
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.司美格鲁肽：治疗心血管-肾脏-代谢综合征的关键药物。
Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3.
7
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.比较 10 种胰高血糖素样肽-1 受体激动剂作为二甲双胍的附加治疗在 2 型糖尿病患者中的疗效和安全性：系统评价。
Front Endocrinol (Lausanne). 2023 Aug 28;14:1244432. doi: 10.3389/fendo.2023.1244432. eCollection 2023.
8
Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide.双脂肪酸和脯氨酸-丙氨酸-丝氨酸（PAS）多肽修饰的长效胰高血糖素样肽-1（GLP-1）缀合物的设计、合成及生物学评价
Bioorg Med Chem. 2025 Oct 1;128:118266. doi: 10.1016/j.bmc.2025.118266. Epub 2025 Jun 6.
9
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.长期每周一次司美格鲁肽治疗无糖尿病患者的体重减轻的疗效和安全性：系统评价和随机对照试验的荟萃分析。
Am J Cardiol. 2024 Jul 1;222:121-130. doi: 10.1016/j.amjcard.2024.04.041. Epub 2024 Apr 26.
10
Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.在真实人群中，与大麻使用障碍的发病率和复发率降低相关的司美格鲁肽：一项回顾性队列研究。
Mol Psychiatry. 2024 Aug;29(8):2587-2598. doi: 10.1038/s41380-024-02498-5. Epub 2024 Mar 14.
引用本文的文献
1
Incretin-Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists.基于肠促胰岛素的背景胰岛素治疗辅助手段用于管理 1 型糖尿病患者的超重体重：来自意大利临床内分泌学家协会的专家意见观点
Diabetes Metab Res Rev. 2025 Sep;41(6):e70073. doi: 10.1002/dmrr.70073.
2
Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.揭示第二代肠促胰岛素类似物司美格鲁肽和替尔泊肽在1型糖尿病及成人隐匿性自身免疫性糖尿病中的治疗潜力。
J Clin Med. 2025 Feb 15;14(4):1303. doi: 10.3390/jcm14041303.
本文引用的文献
1
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.司美格鲁肽在超重和肥胖 1 型糖尿病患者中的疗效。
Diabetes Technol Ther. 2024 Mar;26(3):184-189. doi: 10.1089/dia.2023.0490.
2
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight.低剂量司美格鲁肽对1型糖尿病超重患者的影响。
Diabetes Res Clin Pract. 2024 Mar;209:111593. doi: 10.1016/j.diabres.2024.111593. Epub 2024 Feb 24.
3
Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.胰高血糖素样肽-1类似物作为1型糖尿病患者的辅助治疗：一项更新的系统评价和荟萃分析。
J Clin Endocrinol Metab. 2023 Dec 21;109(1):279-292. doi: 10.1210/clinem/dgad471.
4
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.2021 年全球 1 型糖尿病发病率、患病率和死亡率，并预测至 2040 年：一项建模研究。
Lancet Diabetes Endocrinol. 2022 Oct;10(10):741-760. doi: 10.1016/S2213-8587(22)00218-2. Epub 2022 Sep 13.
5
Obesity and Chronic Kidney Disease in US Adults With Type 1 and Type 2 Diabetes Mellitus.美国 1 型和 2 型糖尿病成人的肥胖与慢性肾脏病。
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1247-1256. doi: 10.1210/clinem/dgab927.
6
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges.1型糖尿病患者的肥胖：关联、风险及管理挑战
Diabetes Metab Syndr Obes. 2021 Jun 21;14:2807-2827. doi: 10.2147/DMSO.S223618. eCollection 2021.
Zotero 插件